NASDAQ · SONN
Healthcare · Biotechnology
$1.26
Down-$1.84 (-59.35%)
Updated Aug 16, 2026, 5:21 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SONN does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SONN.
SONN research
Company profile and research snapshot.
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 7, 2025 | Chardan Capital | Buy | — |
| Mar 28, 2025 | Chardan Capital | Buy | — |
| Dec 20, 2024 | Chardan Capital | Buy | — |
| Aug 23, 2024 | Chardan Capital | Buy | — |
| May 28, 2024 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Dec 2, 2025
Hyperliquid Strategies Inc completed a business combination with Sonnet BioTherapeutics, creating a digital asset treasury reserve company. The merged entity will trade under the ticker 'PURR' on Nasdaq and aims to provide investors exposure to the HYPE token ecosystem.
Benzinga · Dec 2, 2025
Sonnet BioTherapeutics Holdings has received stockholder approval for its proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC, marking a significant corporate development for the oncology-focused biotechnology company.
globenewswire.com · Nov 18, 2025
PRINCETON, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has adjourned its special meeting of stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on its proposed business combination (the “Business Combination”) with Hyperliquid Strategies Inc (“HSI”) and Rorschach I LLC (“Rorschach”), and the other proposals to be considered at the special meeting.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SONN.
No results
No recent SID articles mention SONN.
